Agora, Inc. Sponsored ADR (API) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the sys ...

Group 1: Momentum Investing Overview - Momentum investing involves following a stock's recent trend, with the strategy of buying high and selling higher, capitalizing on established price movements [1] - The Zacks Momentum Style Score helps investors identify stocks with momentum by focusing on key metrics [2] Group 2: Aveanna Healthcare (AVAH) Analysis - Aveanna Healthcare currently holds a Momentum Style Score of A and a Zacks Rank of 1 (Strong Buy), indicating strong potential for outperformance [3][4] - Over the past week, AVAH shares increased by 15.31%, significantly outperforming the Zacks Medical - Outpatient and Home Healthcare industry, which rose by 1.01% [6] - In a longer timeframe, AVAH shares have risen by 33.4% over the past quarter and 42.27% over the past year, while the S&P 500 only increased by 7.87% and 15.7%, respectively [7] Group 3: Trading Volume and Earnings Outlook - The average 20-day trading volume for AVAH is 1,672,211 shares, indicating a bullish sign with rising stock prices [8] - Over the past two months, three earnings estimates for AVAH have increased, raising the consensus estimate from $0.22 to $0.35 [10] - The positive earnings revisions suggest a promising outlook for AVAH, reinforcing its status as a 1 (Strong Buy) stock with a Momentum Score of A [12]

Company Overview - Dell Technologies currently holds a Momentum Style Score of B, indicating a positive outlook based on its recent performance metrics [2] - The company has a Zacks Rank of 2 (Buy), suggesting strong potential for outperformance in the market [3] Price Performance - Over the past week, Dell's shares increased by 0.49%, while the Zacks Computer - Micro Computers industry rose by 0.73% [5] - In a longer time frame, Dell's shares have appreciated by 8.74% over the past month, outperforming the industry's 7.65% [5] - Over the last quarter, Dell's shares have risen by 18.61%, and they are up 22.12% over the past year, significantly outperforming the S&P 500, which increased by 7.87% and 15.7% respectively [6] Trading Volume - Dell's average 20-day trading volume is 4,426,363 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the past two months, two earnings estimates for Dell have been revised upwards, while none have been lowered, leading to an increase in the consensus estimate from $9.43 to $9.47 [9] - For the next fiscal year, one estimate has moved upwards with no downward revisions during the same period [9] Conclusion - Given the positive momentum indicators and earnings outlook, Dell Technologies is positioned as a strong candidate for investment, reflected in its 2 (Buy) rating and Momentum Score of B [11]

Core Viewpoint - Draganfly Inc. (DPRO) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system reflects changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling pressure that affects stock prices [4]. Recent Performance and Outlook - Draganfly's earnings estimates have seen a notable increase, with the Zacks Consensus Estimate rising by 37.9% over the past three months [8]. - For the fiscal year ending December 2025, the expected earnings per share for Draganfly is -$1.52, unchanged from the previous year [8]. Zacks Rank System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - Draganfly's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [10].

Investors might want to bet on Norsk Hydro ASA (NHYDY) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual inves ...

Dell Technologies (DELL) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power o ...

Group 1 - Sagimet Biosciences Inc. (SGMT) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][4][6] - The Zacks rating system focuses on a company's earnings picture, tracking the Zacks Consensus Estimate for EPS from sell-side analysts, which reflects the company's future earnings potential [2][5] - The recent increase in earnings estimates for Sagimet Biosciences suggests an improvement in its underlying business, likely leading to increased stock price due to investor interest [6][9] Group 2 - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly Zacks Rank 1 stocks averaging a +25% annual return since 1988 [8][10] - Sagimet Biosciences is expected to earn -$1.85 per share for the fiscal year ending December 2025, with a 25.6% increase in the Zacks Consensus Estimate over the past three months [9][11] - The upgrade to Zacks Rank 2 places Sagimet in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10][11]

Core Viewpoint - FirstCash Holdings (FCFS) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on a company's changing earnings picture, which is crucial for near-term stock price movements [2][4]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling actions that affect stock prices [4]. Company Performance and Outlook - The upgrade for FirstCash indicates a positive outlook for its earnings, suggesting potential buying pressure and an increase in stock price [3][5]. - FirstCash is expected to earn $8.03 per share for the fiscal year ending December 2025, with a 1.3% increase in the Zacks Consensus Estimate over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong track record of performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7]. - The upgrade of FirstCash to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

GeoVax Labs Inc. (GOVX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a cha ...

Core Viewpoint - Anika Therapeutics has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on the consensus measure of EPS estimates from sell-side analysts, reflecting the company's changing earnings picture [1][2]. - Changes in future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements [3][5]. Institutional Investor Influence - Institutional investors utilize earnings estimates to determine the fair value of a company's shares, impacting stock price through their large transactions [3]. Business Improvement Indicators - Rising earnings estimates and the Zacks rating upgrade suggest an improvement in Anika's underlying business, which could lead to higher stock prices as investors respond positively [4][9]. Earnings Estimate Revisions for Anika - Anika is projected to earn -$0.14 per share for the fiscal year ending December 2025, with no year-over-year change [7]. - Over the past three months, the Zacks Consensus Estimate for Anika has increased by 7.8% [7]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [6][8]. - Anika's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for near-term price appreciation [9].